Unprecedented global demand for GLP-1 receptor agonists has disrupted standard pharmaceutical manufacturing allocations. Major drugmakers are acquiring specialized fill-finish facilities and re-allocating existing production lines away from secondary therapeutic categories.
Valuation Dynamics in Contract Manufacturing
Contract Development and Manufacturing Organizations (CDMOs) with sterile injectable capacity have seen market valuations surge. Conversely, smaller biotech firms specializing in non-GLP-1 oral solid doses face extended wait times and higher unit costs for third-party production slots.